People: Brooks Automation Inc (BRKS.OQ)

BRKS.OQ on NASDAQ Stock Exchange Global Select Market

17 Jul 2019
Change (% chg)

$-0.03 (-0.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rosenblatt, Michael 

Dr. Michael Rosenblatt, M.D. is Director of the Company. Dr. Rosenblatt currently serves as Chief Medical Officer of Flagship Pioneering, a Cambridge, Massachusetts-based firm that originates new biotech companies. Prior to Flagship Pioneering, from 2009 through 2016, he was Executive Vice President and Chief Medical Officer of Merck & Co., Inc., and prior to that he held various academic positions, including as Dean of Tufts University School of Medicine and the Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. Since 2015 Dr. Rosenblatt has been on the board of Rubius Therapeutics, a publicly traded company using advanced cellular approaches that harness properties of red blood cells to generate novel therapies. He has been a director of the following privately owned companies since 2016: Flagship Pioneering’s Cobalt Biomedicine, Cygnal Therapeutics, and Ohana Biosciences, and Ferring’s USA subsidiary. Dr. Rosenblatt is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women’s, and Boston Children’s hospitals.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 36,740
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 36,740

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joseph Martin


Stephen Schwartz


Lindon Robertson


Maurice Tenney


Jason Joseph


David Jarzynka

As Of  30 Sep 2018